Atsena Therapeutics Receives FDA RPD Designation for X-Linked Retinoschisis Gene Therapy Candidate
On August 14, 2024, Atsena Therapeutics (New Haven, CT, USA), a gene therapy company focused on combating inherited blindness, announced…
Cutting-Edge Ocular Therapies
Advancements in retinal organoid transplantation and stem cell therapies unveiled at APAO 2024 In recent years, there has been remarkable…
latest posts
